Cryo-Cell International (CCEL) vs DaVita (DVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DaVita (DVA) has outperformed Cryo-Cell International (CCEL) over the past year, gaining 33.9% versus a gain of 1.5%. Over five years, DVA leads with a +65.5% price change compared with -66.3% for CCEL. DaVita is the larger company by market cap ($10.13 billion vs $33.5 million), about 302.7 times the size.
On valuation, DaVita trades at a lower forward P/E (9.5x vs 207.5x for Cryo-Cell International). DaVita converts more of its revenue into profit, with a net margin of 5.5% versus -7.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | DVA |
|---|---|---|
| Share price | $4.15 | $161.03 |
| Market cap | $33.46M | $10.13B |
| 1-day change | 0.00% | +3.00% |
| YTD return | +20.64% | +41.74% |
| 1-year return | +1.47% | +33.91% |
| 5-year return | -66.34% | +65.52% |
| P/E ratio (TTM) | — | 12.19 |
| Forward P/E | 207.50 | 9.52 |
| EPS (TTM) | $-0.24 | $13.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $31.57M | $13.64B |
| Revenue growth (YoY) | -1.31% | +6.46% |
| Net income (latest FY) | $-2.43M | $746.80M |
| Gross margin | 76.63% | — |
| Operating margin | 1.53% | 14.98% |
| Net margin | -7.70% | 5.47% |
| 52-week high | $5.45 | $247.49 |
| 52-week low | $2.72 | $101.00 |
| Distance from 52-week high | -23.85% | -34.93% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +38.04% |
| Average volume | 13.02K | 738.70K |
| Shares outstanding | 8.06M | 62.90M |
| Employees | 72 | 78,000 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 302.7 times larger than Cryo-Cell International by market value ($10.13B vs $33.46M).
- DVA has outperformed CCEL by 32.4 percentage points over the past year.
- DaVita is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -7.7 cents for Cryo-Cell International.
- DaVita grew revenue faster in its latest fiscal year (+6.46% vs -1.31%).
About Cryo-Cell International
CCEL stock →Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
Health Care · Misc Health and Biotechnology Services · 72 employees
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
CCEL vs DVA FAQ
Which is bigger, Cryo-Cell International or DaVita?
DaVita (DVA) is larger, with a market capitalization of $10.13B compared with $33.46M for Cryo-Cell International (CCEL).
Which stock has performed better over the past year, CCEL or DVA?
DVA returned +33.91% over the past 12 months, compared with +1.47% for CCEL (price return, excluding dividends). Past performance does not predict future results.
Are Cryo-Cell International and DaVita in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.